Colorectal Cancer Chemoprevention: Is This the Future of Colorectal Cancer Prevention?

Table 2

Results in adenoma incidence in COXIB trials.

Study	Year	Cohort	N° cases	Intervention	End point	RR
APPROVe	2006	Prior adenoma	2587	25 mg rofecoxib versus placebo	Adenoma incidence	0.76; 0.69–0.83
APC	2006	Prior adenoma	2035	200 mg bid versus 400 mg bid versus placebo*	Adenoma incidence	0.67; 0.55
PreSAP	2006	Prior adenoma	1561	400 mg once versus placebo	Adenoma incidence	0.64; 0.56–0.75

*Positive for both arms.